Literature DB >> 10979858

Immunology. Therapeutic manipulation of gut flora.

F Shanahan1.   

Abstract

In developed countries as many as two individuals in every thousand suffer from inflammatory bowel disease (ulcerative colitis and Crohn's disease). In his Perspective, Shanahan discusses a new therapeutic approach to treating these conditions in which bacteria normally found in the gut are engineered to produce the anti-inflammatory cytokine interleukin-10 and then are fed as probiotics to mice with these disorders (Steidler et al.).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979858     DOI: 10.1126/science.289.5483.1311

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  18 in total

Review 1.  Intestinal microflora as a therapeutic target in inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Atsushi Toyonaga; Michio Sata
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

2.  Fermented milk-starch and milk-inulin products as vehicles for lactic acid bacteria.

Authors:  Angela Zuleta; María I Sarchi; María E Rio; María E Sambucetti
Journal:  Plant Foods Hum Nutr       Date:  2004       Impact factor: 3.921

3.  Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats.

Authors:  T Kamiya; L Wang; P Forsythe; G Goettsche; Y Mao; Y Wang; G Tougas; J Bienenstock
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

Review 4.  Necrotizing enterocolitis: a practical guide to its prevention and management.

Authors:  Pinaki Panigrahi
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis.

Authors:  Payal Agarwal; Pulkit Khatri; Blasé Billack; Woon-Kai Low; Jun Shao
Journal:  Pharm Res       Date:  2014-06-14       Impact factor: 4.200

6.  Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis.

Authors:  B Sheil; J McCarthy; L O'Mahony; M W Bennett; P Ryan; J J Fitzgibbon; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 7.  Potential uses of probiotics in clinical practice.

Authors:  Gregor Reid; Jana Jass; M Tom Sebulsky; John K McCormick
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

8.  Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity.

Authors:  Osamu Kanauchi; Masanobu Fukuda; Yoshiaki Matsumoto; Shino Ishii; Toyokazu Ozawa; Makiko Shimizu; Keiichi Mitsuyama; Akira Andoh
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

9.  Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium.

Authors:  Nadia Osman; Diya Adawi; Siv Ahrne; Bengt Jeppsson; Göran Molin
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

10.  NOD2/CARD15 and the Paneth cell: another piece in the genetic jigsaw of inflammatory bowel disease.

Authors:  M C Aldhous; E R Nimmo; J Satsangi
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.